New compound targets drug resistant HIV mutant

Maintaining anti-HIV activity against drug-resistant mutants.

A newly developed inhibitor (compound 25a) binds to human immunodeficiency virus (HIV) reverse transcriptase, a viral protein essential for HIV replication.
A newly developed inhibitor (compound 25a) binds to human immunodeficiency virus (HIV) reverse transcriptase, a viral protein essential for HIV replication.

Scientists at the Yale University have developed compounds that maintain anti-HIV movement against drug-resistant mutants superior to anything FDA-endorsed medications. The compounds restrain the capacity of a viral enzyme, called reverse transcriptase, which is basic for HIV replication.

This newly developed inhibitor also called compound 25a also sticks to both the “wild-type” and the mutant forms of the reverse transcriptase.

Studying it in detail, scientists found that the new reverse transcriptase inhibitors were better able to adapt their shapes’ to bind to mutant HIV reverse transcriptase than existing agents.

The researchers report in the online journal eLife.